1027 Garden Street
About EvolusEvolus Inc. is a privately held company focused on bringing highly innovative products and services to the aesthetics market.
CEO: Murthy Simhambhatla
COO: Chris Marmo
CMO: Rui Avelar
13 articles with Evolus
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
5/13/2018Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.
Evolus, Inc. announced that its board of directors has named David Moatazedi as President and Chief Executive Officer.
Here’s a look at eight biopharma companies with upcoming catalysts.
Evolus raised approximately $60M in gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses.
Evolus has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
1/9/2018Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering.
Medytox Files Citizen Petition with FDA Requesting Investigation of Application for Botulinum Drug Product
False statements about a botulinum toxin strain and concerns about integrity of data and the impact on patient safety are at the core of a Citizen Petition filed today asking the U.S. Food and Drug Administration (FDA) not to approve the neurotoxin product made by Daewoong Pharmaceuticals Co., Ltd. that is the subject of a Biological Product Application (BLA) submitted by Evolus Inc.
Evolus Announces Health Canada Acceptance for Review of the New Drug Submission for PrabotulinumtoxinA
Evolus received confirmation from Health Canada that the NDS for prabotulinumtoxinA, a 900 kilodalton Botulinum toxin Type A, for the treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows, has been accepted for review.
Evolus Announces EMA Acceptance For Review Of The Marketing Authorization Application For DWP-450 Neuromodulator
Evolus Announces FDA Acceptance For Review Of The Biologics License Application For DWP-450 Neuromodulator